ArcticZymes Technologies — Board/Management Information 2026

May 28, 2026

ArcticZymes Technologies Strengthens Board with Appointment of Dr. Hanna Pirita Lesch, Supporting Diversification into RNA and Continued Leadership in Cell & Gene Therapy

ArcticZymes Technologies Strengthens Board with Appointment of Dr. Hanna Pirita Lesch, Supporting Diversification into RNA and Continued Leadership in Cell & Gene Therapy

Tromsø, Norway - 28 May 2026 - ArcticZymes Technologies ASA (OSE: AZT) today

announced that, following approval at its Annual General Meeting, Dr. Hanna

Pirita Lesch has been elected to the Company's Board of Directors. Dr. Frank

Mathias has been re-elected as Chair, and Petter Dragesund has been re-elected

as a Board member. Sharon Brownlow steps down from the Board after a period of

valued service.

The appointment directly supports the execution of ArcticZymes' strategy:

diversifying into RNA through the build-out of a dedicated RNA enzyme portfolio,

while continuing to strengthen the Company's established position in cell and

gene therapy and broader advanced biomanufacturing.

Supporting diversification into RNA and continued leadership in cell & gene

therapy

Dr. Lesch brings to the Board directly relevant competencies across both

strategic priorities. As Chief Technology Officer of Aurealis Therapeutics, and

previously CTO of Exothera - an international CDMO focused on viral vector and

mRNA-based therapies - she has led technology strategy, platform development,

and CMC for some of Europe's most advanced RNA and gene therapy programs. Her

hands-on experience scaling RNA manufacturing processes supports ArcticZymes'

diversification into the RNA segment, while her deep expertise in viral vector

and ATMP manufacturing reinforces the Company's continued leadership in cell and

gene therapy.

Equally important, Dr. Lesch combines this strategic perspective with a genuine

understanding of the underlying technology and science. She holds a PhD in

Molecular Medicine and an Adjunct Professorship in Biomedicine and Bioprocessing

at the University of Eastern Finland, has authored more than 35 peer-reviewed

publications, and currently chairs the European Society of Gene and Cell

Therapy's Manufacturing Committee. Earlier in her career, as Gene Therapy Unit

Director at the Kuopio Center for Gene and Cell Therapy and R&D Director

at Finvector and FKD Therapies, she contributed to the development of adenoviral

gene therapy products that progressed to marketing approval.

Continuity and stewardship

Dr. Frank Mathias, CEO of Oxford Biomedica and previously CEO of Rentschler

Biopharma and Medigene AG, continues as Chair. Petter Dragesund, an independent

investor and former Senior Partner and Head of Corporate Finance at Pareto

Securities, continues as a Board member. Their re-election ensures continuity of

governance and strategic direction as the Company executes its growth plan.

Thanks to Sharon Brownlow

The Board and Management extend their sincere thanks to Sharon Brownlow, who is

stepping down after contributing valuable life-sciences industry experience

drawn from her senior roles at Catapult and Cobra Biologics. Her perspective has

supported ArcticZymes during an important phase of its development, and the

Company wishes her continued success.

CEO commentary

"Hanna's appointment is a deliberate step to strengthen our Board as we execute

on our strategy - both diversifying into RNA through a dedicated enzyme

portfolio and continuing to build on our leadership in cell and gene therapy.

She brings directly relevant competencies across RNA and viral vector

manufacturing, combined with a deep understanding of the underlying technology

and science - exactly the perspective we need around the Board table as we move

into this next phase," said Michael Akoh, CEO of ArcticZymes Technologies.

"Together with Frank's continued leadership as Chair and Petter's strategic

finance perspective, we have a Board well positioned to support our next phase

of growth. I'd also like to thank Sharon for her contributions during her time

with us - her industry insight has been genuinely valued."

- Ends -

For more information, please contact:

ArcticZymes Technologies ASA

CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15

CFO, Børge Sørvoll Tel +47 952 90187

ir@arcticzymes.com

About ArcticZymes Technologies

ArcticZymes Technologies is a Norwegian life sciences company focused on the

development, manufacturing, and commercialization of novel recombinant enzymes

for use in molecular research, in vitro diagnostics (IVD), and biomanufacturing.

The company has pioneered salt-active nucleases and continues to develop enzyme

solutions that support efficient and reliable production of advanced

therapeutics.

For more information, please visit the website: www.arcticzymes.com